Glenmark Pharmaceuticals has voluntarily recalled 114 batches of potassium chloride extended-release capsules due to a flaw in the medication that could lead to cardiac arrest. Last week, American Health Packaging, acting on behalf of BluePoint Laboratories, also recalled 21 batches of the same capsules. The recall was issued because of the failed dissolution of the capsules, which could potentially result in high potassium levels or hyperkalemia.
The US Food and Drug Administration (FDA) reported that the drug recalls took place last week, with hyperkalemia possibly causing an irregular heartbeat that could lead to cardiac arrest. The recall for Glenmark was issued one Monday, followed by the recall for BluePoint the next day. Both capsules were manufactured by Glenmark, with no reports of hyperkalemia or serious adverse events related to the recall so far.
The potassium chloride extended-release capsules are intended for patients with low potassium levels or hypokalemia and are available in bottles of 100 and 500. The FDA has listed the recalled batch numbers for Glenmark and BluePoint capsules on their website. Consumers who have these capsules should consult with their physician or healthcare provider before stopping their use and seek medical advice if they have experienced any issues related to the drug product.